These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31188892)

  • 21. Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage III colon cancer.
    Peng J; Zhang R; Zhao Y; Wu X; Chen G; Wan D; Lu Z; Pan Z
    Chin J Cancer; 2017 Dec; 36(1):96. PubMed ID: 29268783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tim3 and PD-1 as a therapeutic and prognostic targets in colorectal cancer: Relationship with sidedness, clinicopathological parameters, and survival.
    Mokhtari Z; Rezaei M; Sanei MH; Dehghanian A; Faghih Z; Heidari Z; Tavana S
    Front Oncol; 2023; 13():1069696. PubMed ID: 37035199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic effect of sidedness in early stage versus advanced colon cancer.
    Kennecke HF; Yin Y; Davies JM; Speers CH; Cheung WY; Lee-Ying R
    Health Sci Rep; 2018 Aug; 1(8):e54. PubMed ID: 30623090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors affecting prognosis in metastatic colorectal cancer patients.
    Eker B; Ozaslan E; Karaca H; Berk V; Bozkurt O; Inanc M; Duran AO; Ozkan M
    Asian Pac J Cancer Prev; 2015; 16(7):3015-21. PubMed ID: 25854399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
    Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
    Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mismatch repair deficiency screening in colorectal carcinoma by a four-antibody immunohistochemical panel in Pakistani population and its correlation with histopathological parameters.
    Hashmi AA; Ali R; Hussain ZF; Faridi N; Khan EY; Bakar SMA; Edhi MM; Khan M
    World J Surg Oncol; 2017 Jun; 15(1):116. PubMed ID: 28651545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness.
    Bencsikova B; Budinska E; Selingerova I; Pilatova K; Fedorova L; Greplova K; Nenutil R; Valik D; Obermannova R; Sheard MA; Zdrazilova-Dubska L
    BMC Cancer; 2019 Jul; 19(1):687. PubMed ID: 31307428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer?
    Rossi S; Basso M; Strippoli A; Schinzari G; D'Argento E; Larocca M; Cassano A; Barone C
    Clin Colorectal Cancer; 2017 Dec; 16(4):264-274. PubMed ID: 28412137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial.
    Noepel-Duennebacke S; Arnold D; Hertel J; Tannapfel A; Hinke A; Hegewisch-Becker S; Reinacher-Schick A
    Clin Colorectal Cancer; 2018 Dec; 17(4):e733-e739. PubMed ID: 30145148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
    Song A; Eo W; Lee S
    World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated fibrinogen plasma level is not an independent predictor of poor prognosis in a large cohort of Western patients undergoing surgery for colorectal cancer.
    Pedrazzani C; Mantovani G; Salvagno GL; Baldiotti E; Ruzzenente A; Iacono C; Lippi G; Guglielmi A
    World J Gastroenterol; 2016 Dec; 22(45):9994-10001. PubMed ID: 28018106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammation-based prognostic scores as indicators to select candidates for primary site resection followed by multimodal therapy among colorectal cancer patients with multiple metastases.
    Shimura T; Toiyama Y; Saigusa S; Imaoka H; Okigami M; Fujikawa H; Hiro J; Kobayashi M; Ohi M; Araki T; Inoue Y; Uchida K; Mohri Y; Kusunoki M
    Int J Clin Oncol; 2017 Aug; 22(4):758-766. PubMed ID: 28299463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer.
    Wiesweg M; Reis H; Köster T; Goetz M; Worm K; Herold T; Paul A; Dechêne A; Schumacher B; Markus P; Virchow I; Kostbade K; Wolf N; Zaun G; Metzenmacher M; Schmid KW; Schuler M; Kasper S
    Clin Colorectal Cancer; 2018 Jun; 17(2):e331-e352. PubMed ID: 29526493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.
    Sunakawa Y; Ichikawa W; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Nakajima T
    Clin Colorectal Cancer; 2017 Sep; 16(3):e171-e180. PubMed ID: 27856123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of inflammation-based scores in patients receiving radical resection for colorectal cancer.
    Wang F; He W; Jiang C; Guo G; Ke B; Dai Q; Long J; Xia L
    BMC Cancer; 2018 Nov; 18(1):1102. PubMed ID: 30419863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
    Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
    Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis.
    Shigematsu Y; Inamura K; Yamamoto N; Mise Y; Saiura A; Ishikawa Y; Takahashi S; Kanda H
    BMC Cancer; 2018 Oct; 18(1):980. PubMed ID: 30326864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative Neutrophil-to-Lymphocyte Ratio is a Better Prognostic Serum Biomarker than Platelet-to-Lymphocyte Ratio in Patients Undergoing Resection for Nonmetastatic Colorectal Cancer.
    Choi WJ; Cleghorn MC; Jiang H; Jackson TD; Okrainec A; Quereshy FA
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S603-13. PubMed ID: 25900206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of systemic inflammatory and nutritional scores in colorectal cancer patients who underwent potentially curative resection.
    Tokunaga R; Sakamoto Y; Nakagawa S; Izumi D; Kosumi K; Taki K; Higashi T; Miyata T; Miyamoto Y; Yoshida N; Baba H
    Int J Clin Oncol; 2017 Aug; 22(4):740-748. PubMed ID: 28213742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.